{
  "nctId": "NCT04280705",
  "officialTitle": "Adaptive COVID-19 Treatment Trial (ACTT)",
  "briefTitle": "Adaptive COVID-19 Treatment Trial",
  "status": "Completed",
  "phase": ["Phase 3"],
  "studyType": "Interventional",
  "conditions": ["COVID-19", "SARS-CoV-2 Infection"],
  "interventions": [
    {
      "type": "Drug",
      "name": "Remdesivir",
      "description": "200 mg loading dose on day 1, followed by 100 mg daily for up to 9 additional days"
    },
    {
      "type": "Drug",
      "name": "Placebo",
      "description": "Matching placebo administered on the same schedule"
    }
  ],
  "sponsor": {
    "name": "National Institute of Allergy and Infectious Diseases (NIAID)",
    "class": "NIH"
  },
  "locations": [
    {
      "facility": "University of Nebraska Medical Center",
      "city": "Omaha",
      "state": "Nebraska",
      "country": "United States",
      "status": "Completed"
    }
  ],
  "enrollment": {
    "count": 1062,
    "type": "Actual"
  },
  "startDate": "2020-02-21",
  "completionDate": "2020-04-19",
  "primaryOutcomes": [
    {
      "measure": "Time to recovery",
      "timeFrame": "Day 1 through Day 29",
      "description": "Days until participant met the recovery criterion of being well enough for hospital discharge"
    }
  ],
  "eligibility": {
    "criteria": "Hospitalized adults with laboratory-confirmed SARS-CoV-2 infection and evidence of lower respiratory tract involvement",
    "sex": "All",
    "minimumAge": "18 Years",
    "healthyVolunteers": false
  },
  "url": "https://clinicaltrials.gov/study/NCT04280705"
}